Aspirin (acetylsalicylic acid) has become one of the most commonly used drugs, given its
role as an analgesic, antipyretic and agent for cardiovascular prophylaxis. Several decades …

Background Accumulating evidence supports an effect of aspirin in reducing overall cancer
incidence and mortality in the general population. We reviewed current data and assessed …

Abstract The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of
Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic …

From the dawn of civilization, humanity has dreamed of immortality. So why didn't the
discovery of the anti-aging properties of mTOR inhibitors change the world forever? I will …

Background Low-dose aspirin has proven effectiveness in secondary and primary
prevention of cardiovascular events, but is also associated with an increased risk of major …

Aspirin as a possible treatment of cancer has been of increasing interest for over 50 years,
but the balance of the risks and benefits remains a point of contention. We summarise the …

Therapeutic cancer prevention is a developing area that can gain a lot from the successes in
the prevention of cardiovascular diseases. Although weight control and physical activity are …

Evidence on aspirin and cancer comes from two main sources:(1) the effect of aspirin upon
biological mechanisms in cancer, and (2) clinical studies of patients with cancer, some of …

Background Preclinical, epidemiological, and randomised data indicate that aspirin might
prevent tumour development and metastasis, leading to reduced cancer mortality …

Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus)
and Everolimus, are gerosuppressants, which suppress cellular senescence. Rapamycin …